research use only
Cat.No.S3694
|
In vitro |
Water : 43 mg/mL
DMSO
: 4 mg/mL
(18.55 mM)
Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 215.63 | Formula | C6H13NO5.HCl |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 66-84-2 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | 2-Amino-2-deoxy-glucose HCl, Chitosamine HCl | Smiles | C(C1C(C(C(C(O1)O)N)O)O)O.Cl | ||
| In vitro |
Glucosamine enters the hexosamine biosynthetic pathway (HBP) downstream of the rate-limiting step catalyzed by the GFAT (glutamine:fluctose-6-phosphate amidotransferase), providing UDP-GlcNAc substrates for O-linked β-N-acetylglucosamine (O-GlcNAc) protein modification. Glucosamine inhibits proteasomal activity and the proliferation of ALVA41 prostate cancer cells. The inhibition of proteasomal activity results in the accumulation of ubiquitinated proteins, followed by induction of apoptosis. Glucosamine downregulates proteasome activator PA28γ and overexpression of PA28γ rescues the proteasomal activity and growth inhibition mediated by glucosamine. Glucosamine inhibits the proliferation of RCC cells by promoting cell cycle arrest at G0/G1 phase, but not promoting apoptosis.
|
|---|---|
| In vivo |
Glucosamine could significantly inhibit the production of nitric oxide and prostagladin E2 and suppress the progression of adjuvant arthritis in rats. Glucosamine may be expected as a novel anti-inflammatory agent for treatment of rheumatoid arthritis. Administration of glucosamine normalizes cartilage metabolism, so as to inhibit the degradation and stimulate the synthesis of proteoglycans, and to restore the articular function. Glucosamine has been demonstrated to prolong the allogeneic cardiac allograft survival by repressing the activation of T-lymphoblasts and dendritic cells.
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.